HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

L’Oréal “Women of Worth”

This article was originally published in The Rose Sheet

Executive Summary

Karen Stark - founder of the "HUGS Project," which sends "hugs" (handmade wearable items for warming or cooling, depending on the season) and care packages to U.S. troops serving overseas - is chosen by popular vote as L'Oreal's Women of Worth National Honoree. Voting for the award opened in early October (1"The Rose Sheet" Oct. 15, 2007, p. 8). Stark will receive $25,000 for the HUGS Project, on top of the $2,500 awarded to all 13 Women of Worth honorees for their respective non-profit and $2,500 donated in each woman's name to The Ovarian Cancer Research Fund, with which L'Oreal Paris has had a charitable partnership for 10 years, firm notes...

You may also be interested in...



L’Oreal Stresses Corporate Responsibility With Creation of L’Oréal Foundation

The L'Oréal Corporate Foundation is "an additional step in our determination to look beyond our economic success towards a broader notion of social responsibility," the company announces Oct. 9

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015059

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel